

Meeting Minutes

Subject:	Louisiana Department of Health and Hospitals Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 118
Date:	October 31, 2012
Members Present:	▪ Mary Gauthier-Lewis, PharmD ▪ James E. Hussey, MD ▪ James G. Lu, M.D. ▪ Edward C. Mader Jr., MD ▪ Marty R. McKay, RPh ▪ Senator Fred Mills ▪ Melvin Murrill, MD ▪ Representative J. Rogers Pope ▪ Leonard Weather Jr., MD ▪ Rodney Wise, MD ▪ Pamela Wiseman, MD ▪ Neil Wolfson, M.D. ▪ Lolie C. Yu, MD
DHH/Pharmacy Program Staff Present:	▪ Rachel Broussard, RPh ▪ Germaine Becks-Moody, PhD, BHSF Program Manager ▪ Madeline McAndrews ▪ Amanda Caire ▪ Calder Lynch ▪ Gabrielle Stewart ▪ Melwyn Wendt RPh ▪ Timothy Williams ▪ Mary Wolf
Contractors Present:	▪ Chris Andrews, PharmD, Magellan Medicaid Administration ▪ Julie Pritchard, PharmD, Magellan Medicaid Administration ▪ Sandy Blake, University of Louisiana at Monroe (ULM) ▪ Rebecca Hebert, University of New Orleans (UNO) ▪ Jennifer Pickett, Certified Court Reporter
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:25 a.m.

Parliamentary Business

1. **Introduction of Members and Roll Call.** Committee Members and staff introduce themselves. Mr. McKay announced that the agenda would be adjusted slightly until another person shows up to approve the minutes. Mr. McKay lets Ms. Sullivan give the report.
2. **Bylaws Subcommittee Report.** Mr. McKay had to reorder the agenda and the bylaws Subcommittee report will be skipped.
3. **Approval of Minutes.** Mr. McKay takes the meeting back to the agenda and to the approval of the minutes. Dr. Weather offered a motion to approve the minutes. Dr. Murrill seconded the motion which passed.

Reports

1. **Background.** Ms. Sullivan provides the background of forming the committee. Established under Louisiana Revised statute 45:153.3. Purpose is to develop a preferred Drug List with no prior authorization, make recommendations for additions and deletions for the preferred Drug List, to advise the Sec of DHH on policy recommendation related to the administration of the Medicaid Pharmacy program. Committee make-up is 21 members appointed by the Governor and confirmed by the Senate. Committee must abide by code of governmental ethics. Bylaws to stay the same at this time. No statutory updates. Proposed bylaws will be sent out two weeks prior to the next meeting. Members can vote to amend bylaws.
2. **Code of Ethics.** Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. Section 115 prohibits a public servant from soliciting or accepting anything of economic value from any person who has contractual business or a financial relationship with the agency. Committee members cannot receive honorariums, reimbursements or compensation of any kind including grants from pharmaceutical companies that have items on the Preferred Drug List or matters before the committee. A P&T Committee member can attend conferences and seminars put on by drug companies that have items on the Preferred List or matters before the P&T committee, as long as the member pays their own expenses for the trip. Committee members who are employees of a university cannot solicit grants on behalf of the university. Members do not have to file financial disclosure statements. If anyone has personal ethical questions, please visit the Board of Ethics at www.ethics.state.la.us or contact Kim Sullivan at; Kimberly.sullivan@la.gov.
3. **Rachel Broussard from DHH provides report.** Ms. Broussard called committee members attention to the packet they received with the Prior Authorization (PA) monthly report, the annual report. Pointing out in January and February of 2012 there was a spike in Prior Authorizations (Attachment A). Also in the packet is the Preferred Drug List that was from May 2, 2012 meeting (Attachment B).

New Business

1. **Mr. Lynch** provides a presentation to the committee.

An overview of some of the major changes occurring in the Medicaid Pharmacy Program: Effective 01 NOV 2012, pharmacy services for members enrolled in the 3 traditional pre-paid managed care

plans will be administered by those plans rather than the Fee for Service Medicaid. This affects approximately 460,000 Medicaid lives. More information is available about this change on the website: www.makingmedicaidbetter.com, including notices to the pharmacy providers about how to prepare for the change.

Regarding the reimbursement change, effective September 5th 2012, DHH moved to an average acquisition cost reimbursement for pharmacy services at AAC + a markup of 10% for generics and 1% for brands + a dispensing fee the \$10.51. Those new rates are available online now on the LA Medicaid website as well as on the Myers and Stauffer website.

2. **Public Testimony.** In accordance with state law and the P&T Committee's Bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review of Therapeutic Classes.

Presenter	Representing	Drug/Issue
Julia Compton	Novartis	Exelon Patch
Mr. Parris Pope	Forest Labs	Viibryd/Vilazodone
Kirsten Mar, Pharm D	Eli Lilly	Cymbalta
Ann Wicker, Pharm D	Pfizer	Pristiq
Ms. Attie Crandell	UCB	Neupro
Victoria Vardes	Janssen	Invega Sustenna
Brittany Howard	Mental Health America of LA	Open access to antipsychotic medications
Tim Burke	Astra Zeneca	Seroquel XR
David Precise	National Alliance of Mental Illness of LA	Protecting the recovery of individuals with mental illness, Restricting access to FDA approved antipsychotics, and Antipsychotic meds are not interchangeable
Manny Garcia	Sunouion	Lurasidone (Latuda) Aripiprazole on the PDL
Dr. Kathleen Murphy	Ostura America Pharm/Psychiatrist	Aripiprazole
Dr. Fran Kaiser	Merck	Saphris
Dr. Zahid Imran	Private Practice in Baton Rouge	Guideline on prescribing Seroquel XR
Danket VYas, M.D.	Psychiatric Practice, Inpatient/Outpatient	Invega Sustenna
Julia Compton, Pharm D	Novartis	Ferapt

Shane Perilloux	Teva Respiratory	upcoming launch Pro Air HFA
Mike Donze	BI	Combivent
Speaker Marilyn		Combivent Respimat Protopic
Eddilisa Martin	Abbott	Humira
Brad Clay	Amgen	Enbrel
Shane Perilloux	Teva Respiratory	QVAR
Sarah Cattern	AZ	Symbicort Pulmicort Flex
James Osborne	GSK	Advair Flovent
Dr. Fran Kaiser	Merck	Dulera
Kevin Brown	Astellas Pharm	Protopic
Marilyn Ripoe	Astellas	Protopic
Shane Perilloux	TEVA	Qnasl
Ann Smallwood	Bristol Meyers Squibb	Sprycel
Ann Wicker	Pfizer	Oral oncology agents
Chris Murphy	GlaxoSmithKline	Votrient/Tykerh
Dr. John Rainey	Louisiana Oncology Society	Erivedge
Denine Coleman	Bausch and Lomb	Besivance
Rupa Shah	Purdue Pharma L.P. Stanford CT	Intermezzo (Zolpidem Tartrate Sublingual Tablets)
Ann Wicker	Pfizer	Chantix
Jennifer Robinson, Pharm D.	Shire Pharmaceuticals	Vyvanese/Intuniv
Kirsten Mar, Pharm D	Eli Lilly	Strattera
Cathy Tugwell	Amylin	Bydureon
Milton Kleinpeter	Amylin	Bydureon
Paula Jimenez	Sanofi Pasteur	Sklice Lotion

I. Therapeutic Class Reviews

Thirty four (34) therapeutic classes were reviewed. Mr. McKay explained the Committee's review procedures. Monograph summaries were sent to the Committee prior to the meeting. Public comment was received for each therapeutic class prior to Committee discussion and action in accordance with state law and the P&T Committees Bylaws. Committee Proceedings Follow.

Prior to the category reviews, Dr. Andrews covered points of the calculations and projections.

Alzheimer's Agents

Dr. Wolfson makes the motion to accept. Dr. Weather seconds the motion. After discussion a pharmaceutical representative Ms. Compton yielded her time back to the committee. A roll call vote was taken and the original motion passed with all in favor. Statistics on the use will be reviewed on the next meeting.

Committee recommendations for the PDL are:

- Donepezil
- Donepezil ODT
- Exelon patch

Antidepressants Other

Dr. Hussey makes a motion to accept the recommendations. Dr. Weather seconds the motion. Mr. Parris from a pharmaceutical company presents Viibryd. Ms. Wicker presents Pristiq. Roll call was taken and the motion passed with all in favor.

Committee recommendations for the PDL are:

- All Forms of Generic Bupropion
- Mirtazapine & ODT
- Trazodone
- Venlafaxine ER capsule

Antidepressants SSRI

Dr. Hussey makes the motion to accept, Dr. Wolfson seconds the motion. After discussion and no pharmaceutical manufacturer's requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Citalopram tab and soln
- Escitalopram tab
- Fluoxetine tab, soln, caps
- Fluvoxamine
- Paroxetine tab
- Sertraline tab and soln

Antihistamines Minimally Sedating

Dr. Weathers makes the motion to accept, Dr. Wolfson seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Cetirizine
- Levocetirizine
- Loratadine

Antihypertensive

Dr. Wolfson makes the motion to accept, Dr. Lu seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Catapres-TTS patch
- Clonidine generic
- Guanfacine
- Methyldopa
- Methyldopa/Hydrochlorothiazide oral

Antihyperuricemics

Dr. Wolfson makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. There was no requested discussion and no pharmaceutical manufacturers' requests to make presentations, the motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Allopurinol
- Probenecid
- Probenecid combination with Colchicine

Antiparkinson's

Dr. Wolfson makes the motion to accept, Dr. Weather seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Ms. Crandle from UCB on Neupro and transdermal system, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Benztropine
- Carbidopa/levodopa
- Pramipexole
- Ropinirole
- Selegiline tab/cap
- Trihexyphenidyl tab/elixir

Antipsychotics

Dr. Wolfson makes the motion to accept, Dr. Lu seconds the motion after many public speakers; both pharmaceutical reps and persons speaking on behalf of the various psychiatric organizations. Roll call was taken and the motion carried. Dr. Gauthier-Lewis, Dr. Mader, Dr. Murrill, and Dr. Weather were against.

Dr. Hussey made a motion to remove Seroquel, Quetiapine, and olanzapine from the preferred list for both generic and brand forms. Dr. Wolfson seconded the motion. Tim Burton made a public comment that Seroquel and Seroquel XR are not A/B rated and have different dosing, indications, and are not interchangeable. Mr. McKay clarified the motion for removal of the Drugs motioned by Dr. Hussey as: Zyprexa/olanzapine from the formulary, Seroquel and its generic equivalents in all forms and fashion. Dr. Andrews clarified that Olanzapine was recommended as a non-preferred. Mr. McKay clarified that a yes vote was to remove Seroquel and its generic equivalent from the PDL. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the motion failed. Dr. Lewis, Dr. Mader, Senator Mills, Dr. Murrill, Rep Pope, Dr. Weather, Dr. Wiseman, and Dr. Yu were against.

Dr. Hussey made a motion to remove Latuda from the preferred list. Dr. Wolfson seconded the motion. Mr. McKay announced an amendment to the motion to remove Latuda. Dr. Hussey withdrew the motion to remove Latuda from the PDL list based on the discussions.

Committee recommendations for the **PDL** are:

- | | |
|-------------------------------------|----------------------------|
| • Amitriptyline/perphenazine oral | • Olanzapine tab/ODT |
| • Chlorpromazine oral | • Orap |
| • Clozapine oral | • Perphenazine oral |
| • Fanapt titration pak/tab | • Risperdal Consta inj |
| • Fluphenazine tab/inj | • Risperidone tab/soln/ODT |
| • Geodon IM | • Seroquel & Seroquel XR |
| • Haloperidol lactate conc/oral/inj | • Thioridazine oral |
| • Haloperidol decanoate inj | • Thiothixene oral |
| • Latuda oral | • Trifluoperazine oral |
| • Moban oral | • Ziprasidone cap |

Topical Antipsoriatics

Dr. Weather makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the **PDL** are:

- Calcipotriene ointment and solution
- Dovonex cream

Bile Salts

Dr. Wolfson makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ursodiol 300 mg capsule

Bronchodilators

Dr. Wolfson makes the motion to accept, Dr. Mader seconds the motion. After pharmaceutical manufacturers' presentation by Shane Perilloux from medical liaison on upcoming launch, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Albuterol nebulizer solutions
- ProAir HFA
- Proventil HFA
- Albuterol tab/syrup
- Terbutaline oral

COPD

Dr. Wolfson makes the motion to accept, Dr. Weather seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Speaker on Combivent Respimat, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Atrovent HFA
- Combivent
- Ipratropium nebulizer
- Ipratropium/Albuterol combination nebulizer
- Spiriva

Cytokine Antagonists

Dr. Murrill makes the motion to accept, Dr. Wolfson seconds the motion. After pharmaceutical manufacturers' representatives Lisa Martin from Abbott Laboratories yields time back to the committee and Brad Clay medical science liaison yields time back as well, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Enbrel

- Humira

Emollients

Dr. Wolfson makes the motion to accept, Dr. Mader seconds the motion. After pharmaceutical manufacturers' Dr. Fran Frasier from Merck, James Osbourne, Shane Perilloux, and Sarah with Astra Zeneca yield time back to the committee, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ammonium lactate cream/lotion
- Lactic Acid cream/lotion

Atopic Dermatitis

Dr. Wolfson makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Marilyn on Protopic, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Elidel

Glucocorticoids Inhaled

Dr. Wolfson makes the motion to accept, Dr. Mader seconds the motion. All speakers yielded their time back to the Committee. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Advair HFA/Diskus
- Asmanex
- Dulera
- Flovent Diskus/HFA
- Pulmicort Flexhaler
- Pulmicort Respules 0.25 & 0.5mg
- Qvar
- Symbicort

Intranasal Rhinitis Agents

Dr. Wolfson makes the motion to accept, Dr. Murrill seconds the motion. After pharmaceutical manufacturers' presentation by Shane Perilloux on QNASL Beclomethasone nasal inhaler, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Astelin

- Astepro
- Fluticasone
- Ipratropium nasal
- Nasacort AQ
- Nasonex
- Patanase

Leukotriene Modifiers

Dr. Wolfson makes the motion to accept, Dr. Mader seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Montelukast
- Zafirlukast

Neuropathic Pain

Dr. Wolfson makes the motion to accept, Dr. Mader seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Cymbalta
- Lidoderm
- Savella

Dr. Lu makes a motion that the committee would like to see actual vs. projected savings going back 2 years (a review of how the committee's recommendations become actual savings). Senator Mills seconds the motion. A voice vote was called for by Mr. McKay, and the motion passed with a unanimous vote.

Dr. Wiseman makes a motion that the committee be informed of any changes to the PDL that occur after the most recent vote when it is enacted. Dr. Weathers seconds. A voice vote was called for by Mr. McKay, and the motion passed with a unanimous vote.

NSAIDS

Dr. Wolfson makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Diclofenac potassium and SR
- Meloxicam and susp

- Diclofenac sodium
- Etodolac
- Flurbiprofen
- Ibuprofen and susp
- Indocin susp
- Indomethacin caps
- Ketoprofen
- ketorolac
- nabumetone
- Naproxen and susp and naproxen EC
- Naproxen sodium
- oxaprozin
- Piroxicam
- Sulindac
- Vimovo

Oncology Agents

Dr. Wolfson makes the motion to accept, Dr. Weathers seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Ann Smallwood from Bristol Meyers Squibb on Sprycel, Ann Wicker from Pfizer on oral oncology agents, Chris Murphy from GlaxoSmithKline on Votrient, Dr. John Rainey from Louisiana Oncology Society on Erivedge.

Senator Mills makes a motion to defer the Oncology Agents list until next year, Dr. Wolfson seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the motion to defer passed with a unanimous vote.

Dr. Yu makes a motion for a permanent ban on oncology agents as part of the PDL, Dr. Weather seconds the motion. After discussion, Dr. Yu withdraws the motion for a permanent ban. (This class was deferred and not voted on, as of this mtg, oral oncology agents will not be reviewed by this committee.)

Ophthalmic Antibiotics/Steroids Combination

Dr. Gauthier-Lewis makes the motion to accept, Dr. Weathers seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Tobradex suspension
- Neomycin/polymyxin B/Dexamethasone combination
- Tobradex ointment
- Sulfacetamide/Prednisolone combination

Ophthalmic Anti-inflammatories

Dr. Wolfson makes the motion to accept, Dr. Weathers seconds the motion. There are no speakers. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Dexamethasone

- Diclofenac
- Fluorometholone
- Flurbiprofen
- Ketorolac and LS
- Prednisolone acetate

Ophthalmic Antibiotics

Dr. Weather makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Denine Coleman from Bausch and Lomb on Besivance, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the **PDL** are:

- | | |
|---------------------------------------|---------------------------------|
| • Bacitracin/polymyxin B sulfate oint | • Ofloxacin |
| • Bleph-10 | • Neomycin/polymyxin/gramicidin |
| • Ciprofloxacin soln | • Polymyxin/trimethoprim |
| • Erythromycin | • Sulfacetamide soln |
| • Garamycin oint | • Tobramycin |
| • Gentamicin drops/oint | • Tobrex oint |
| • Ilotycin | • Vigamox |
| • Moxeza | |

Ophthalmics for Allergic Conjunctivitis

Dr. Weather makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

*Committee recommendations for the **PDL** are:*

- Alrex
- Cromolyn
- Pataday

Ophthalmics, Glaucoma Agents

Dr. Murrill makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the **PDL** are:

- | | |
|--------------------|---------------------|
| • Alphagan P 0.15% | • Latanoprost 2.5ML |
|--------------------|---------------------|

- Betaxolol
- Brimonidine
- Carteolol
- Combigan
- Dorzolamide and Dorzolamide/timolol
- Levobunolol
- Metipranolol
- Pilocarpine
- Timolol
- Travatan and Travatan-Z

Otic Antibiotics

Dr. Weather makes the motion to accept, Dr. Murrill seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ciprodex
- Neomycin/Polymyxin/Hydrocortisone solution suspension
- Ofloxacin

Senator Mills presents that this day is Dr. Wise's last day with the Department

Otic Anti-infectives

Dr. Hussey makes the motion to accept, Dr. Wolfson seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Acetic Acid
- Acetic Acid/Aluminum
- Antipyrine/Benzocaine combination

Sedative Hypnotics

Dr. Mader made a motion to add Zaleplon generic to the PDL; Dr. Gauthier-Lewis seconded the motion. After discussion and no presentation the motion failed. Dr. Gauthier-Lewis, Dr. Mader, and Dr. Wiseman were in favor, all others opposed.

Rica Shaw spoke on Intermezzo.

New motion was made to accept the class as recommended, motion was seconded, roll call was taken and the motion to accept passed with a unanimous vote.

Committee recommendations for the PDL are:

- Chloral hydrate
- Temazepam
- Triazolam

- Zolpidem

Smoking Cessation

Dr. Wolfson makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After discussion and pharmaceutical manufacturers' presentation by Ann Wicker from Pfizer on Chantix, roll call was taken and the original motion passed with Dr. Gauthier-Lewis, Senator Mills, and Dr. Weather against.

Committee recommendations for the PDL are:

- Bupropion SR
- Nicotine Gum, lozenge, patch

Steroids Topical, High Potency

Dr. Weather makes the motion to accept, Dr. Gauthier-Lewis seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Betamethasone dipropionate cr/lotion
- Betamethasone diprop/prop glycol cr
- Betamethasone val cr
- Beta-val cr
- Fluocinonide cr/soln/emollient
- Triamcinolone acetonide cr/oint

Steroids Topical, Low Potency

Dr. Weather makes the motion to accept, Dr. Yu seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Derma-Smoothe FS
- Desonide Cream and Ointment
- Hydrocortisone cream/ointment/lotion
- Hydrocortisone/Mineral Oil/Petrolatum combination

Steroids Topical, Medium Potency

Dr. Gauthier-Lewis makes the motion to accept, Dr. Mader seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Fluticasone propionate ointment/cream
- Hydrocortisone Butyrate soln
- Hydrocortisone Valerate cream/ointment
- Mometasone furoate soln/cream/ointment
- Prednicarbate cream

Steroids Topical, Very High Potency

Dr. Weather makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Clobetasol propionate
- Halobetasol propionate cream/ointment

Stimulants

Dr. Hussey makes the motion to accept, Dr. Yu seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Adderall XR
- Amphetamine Salt Combo Immediate Release
- Daytrana
- Dexmethylphenidate
- Dextroamphetamine
- Focalin
- Focalin XR
- Intuniv
- Metadate CD
- Methylphenidate Chewable & Solution
- Methylphenidate IR and ER
- Strattera
- Vyvanse

II. Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class. The reviews at this meeting were on new products in classes reviewed at the May 2, 2012 meeting. Five (5) new drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

Analgesic, Narcotic Short

Dr. Wolfson makes the motion to accept, Dr. Weather seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the NPDL are:

- Primlev
- Subsys

Bydureon

Dr. Gauthier-Lewis makes the motion to accept, Dr. Wolfson seconds the motion. After pharmaceutical manufacturers' presentation by Kathy on Bydureon, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the NPDL are:

- Bydureon

Antiparasitics

Dr. Wolfson makes the motion to accept, Dr. Yu seconds the motion. After pharmaceutical manufacturers' presentation by Paula on Sklice Lotion, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the NPDL are:

- Sklice

Bladder Relaxants

Dr. Weather makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the NPDL are:

- Gelnique Pump (3% oxybutynin gel)

Omontys

Dr. Wolfson makes the motion to accept, Dr. Yu seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the NPDL are:

- Omontys

Next Steps

Therapy classes to be reviewed for the May meeting will be the same as those reviewed May 2012.


Next Meeting Date

The next committee meeting is scheduled for May 1, 2013.

Adjournment

Dr. Weather offered the motion to adjourn the meeting. Dr. Wiseman seconds the motion. The meeting adjourned at 2:21 p.m.

Marty McKay
11-6-13



6/12/2012

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
1	ADD/ADHD			
	Stimulants and Related Agents	Amphetamine Salt Combo (Generic; Adderall®)	Amphetamine Salt Combo ER (Generic Only)	
		Amphetamine Salt Combo ER (Adderall XR® - Brand Only)	Armmodafinil (Nuvigil®)	
		Atomoxetine (Strattera®)	Clonidine Extended-Release (Kapvay®)	
		Dexamethylphenidate (Focalin® - Brand Only)	Dexamethylphenidate (Generic Only)	
		Dexamethylphenidate ER (Focalin XR®)	Dextroamphetamine ER (Generic; Dexadrine®)	
		Dextroamphetamine (Generic)	Dextroamphetamine Solution (Procentra®)	
		Guanfacine ER (Intuniv®)	Methylphenidate Solution (Generic)	
		Lisdexamfetamine (Vyvanse®)	Methamphetamine (Generic; Desoxyn®)	
		Methylphenidate (Generic; Metadate CD®)	Methylphenidate ER (Ritalin LA®)	
		Methylphenidate ER (Generic; Concerta; Metadate CD®)	Modafinil (Provigil®)	
		Methylphenidate IR (Methylphenidate Chewable & Solution®)		
		Methylphenidate SR (Ritalin SR®)		
		Methylphenidate Transdermal Patches (Daytrana®)		
2	ALLERGY			
	Antihistamines - Minimally Sedating			
		Cetirizine Syrup OTC	Acrivastin/Pseudoephedrine (Semprex-D®)	
		Cetirizine Syrup Rx	Cetirizine Chewable Tablet OTC	
		Cetirizine Tablet OTC	Cetirizine Solution 5mg/5cc OTC	
		Cetirizine-D OTC	Desloratadine Tablet (Claritin®)	
		Fexofenadine Tablet 30mg, 60mg, 180mg (Generic Only)	Desloratadine ODT (Claritin ODT®)	
		Fexofenadine-D 12-hour (Generic Only)	Desloratadine Syrup (Claritin®)	
		Fexofenadine-D 24-hour (Generic Only)	Desloratadine/Pseudoephedrine (Claritinex-D 12-hour®)	
		Loratadine Tab OTC (Generic Only)	Desloratadine/Pseudoephedrine (Claritinex-D 24-hour®)	
		Loratadine ODT Tablet OTC (Generic Only)	Fexofenadine Tablet 30mg, 60mg, 180mg (Allegra - Brand Only)	
		Loratadine-D Tablet (Generic Only)	Fexofenadine ODT Tablet (Allegra ODT®)	
		Loratadine Syrup OTC (Generic Only)	Fexofenadine/Pseudoephedrine (Allegra-D 12-hour® - Brand Only)	
			Fexofenadine/Pseudoephedrine (Allegra-D 24-hour® - Brand Only)	
			Fexofenadine Syrup (Allegra Syrup®)	
			Levocetirizine Tablet (Generic; Xyzal®)	
			Levocetirizine Syrup (Generic; Xyzal®)	
			Loratadine Capsule OTC (Claritin® - Brand Only)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
4	ANTIPSYCHOTIC AGENTS			
	Antipsychotic Agents		ORAL	
		Amitriptyline/Perphenazine	Aripiprazole Oral Solution (Ablify Oral Solution [®])	
		Aripiprazole Discontinuation (Ablify [®])	Clozapine (Clozaril; Fazaclo [®])	
		Aripiprazole Tablet (Ablify [®])	Lurasidone (Latuda [®])	
		Asenapine (Saphris [®])	Olanzapine (Zyprexa; Zyprexa Zydis [®])	
		Chlorpromazine	Olanzapine/Fluoxetine (Symbyax [®])	
		Clozapine (Generics Only)	Paliperidone ER (Invega [®])	
		Fluphenazine Elixir	Risperidone ODT (Risperdal [®] - Brand Only)	
		Fluphenazine Tablet	Risperidone Solution (Risperdal [®] - Brand Only)	
		Haloperidol Oral	Risperidone Tablet (Risperdal [®] - Brand Only)	
		Haloperidol Lactate Concentrate		
		Haloperidone Dose pack (Fanapt [®])		
		Haloperidone Tablet (Fanapt [®])		
		Molindone (Moban [®])		
		Perphenazine		
		Pimozide (Orap [®])		
		Quetiapine (Seroquel [®])		
		Quetiapine (Seroquel XR [®])		
		Risperidone ODT (Generic Only)		
		Risperidone Solution (Generic Only)		
		Risperidone Tablet (Generic Only)		
		Thioridazine		
		Thiothixene (Generic; Navane [®])		
		Trifluoperazine (Generic)		
		Ziprasidone (Geodon [®])		
			INJECTIONS	
		Aripiprazole (Ablify [®])	Haloperidol Decanoate (Haldol [®] - Brand Only)	
		Fluphenazine Decanoate	Olanzapine (Zyprexa [®])	
		Haloperidol Decanoate (Generic Only)	Olanzapine (Zyprexa Relprevv [®])	
		Haloperidol Lactate (Generic)	Paliperidone (Invega Sustenna [®])	
		Risperidone (Risperdal Consta [®])		
		Ziprasidone (Geodon [®])		

[illegible]

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Glucocorticoids, Inhalation			
		Beclomethasone MDI (QVAR®)	Budesonide DPI (Pulmicort Flexhaler®)	
		Budesonide Respules 0.25mg; 0.5mg - 8 years old and under	Budesonide Respules 0.25mg; 0.5mg - 9 years old and over	
		Budesonide Respules 0.25mg; 0.5mg (Pulmicort Respules®) - 8 years old and under	Budesonide Respules 0.25mg; 0.5mg (Pulmicort Respules®) - 9 years old and over	
		Budesonide Respules 1mg (Pulmicort Respules®) - 8 years old and under	Budesonide Respules 1mg (Pulmicort Respules®) - 9 years old and over	
		Fluticasone MDI (Flovent®)	Budesonide/Formoterol MDI (Symbicort®)	
		Fluticasone MDI (Flovent HFA Inhaler®)	Ciclesonide (Alvesco®)	
		Fluticasone/Salmeterol DPI (Advair Diskus®)		
		Fluticasone/Salmeterol MDI (Advair HFA®)		
		Mometasone DPI (Asmanex®)		
		Mometasone/Formoterol MDI (Dulera®)		
	Leukotriene Modifiers			
		Montelukast Chewable Tablet (Singulair®)	Montelukast Gran Pack (Singulair Gran Pack®)	
		Montelukast Tablet (Singulair®)	Zafirlukast (Generic Only)	
		Zafirlukast (Accolate® - Brand Only)	Zileuton CR (Zyflo CR®)	
6	DEPRESSION			
	Antidepressants, Other			
		Bupropion IR	Bupropion HBr ER (Aplenzin®)	
		Bupropion SR	Bupropion HCl IR (Wellbutrin®)	
		Bupropion XL	Bupropion HCl SR (Wellbutrin SR®)	
		Duloxetine (Cymbalta®)	Bupropion HCl XL (Wellbutrin XL®)	
		Mirtazapine (Generics only)	Desvenlafaxine (Pristiq®)	
		Mirtazapine ODT (Generics only)	Mirtazapine (Remeron®)	
		Trazodone	Mirtazapine ODT (Remeron ODT®)	
		Venlafaxine ER Capsule (Effexor XR® - Brand Only)	Nefazodone	
		Venlafaxine IR Tablet	Selegiline Patch (Emsam®)	
			Trazodone ER (Oleptro®)	
			Venlafaxine ER Capsule (Generic)	
			Venlafaxine ER Tablet (Generic; Schwarz; Upstate)	
			Vilazodone (Viibryd®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram Tablet (Generic)	Citalopram Solution	
		Fluoxetine Capsule (Generic)	Citalopram Tablet (Celexa®)	
		Fluoxetine Tablet 10mg	Escitalopram Solution (Lexapro®)	
		Fluoxetine Solution	Escitalopram Tablet (Lexapro®)	
		Fluvoxamine Oral	Fluoxetine Tablet 20mg	
		Paroxetine Suspension (Paxil®)	Fluoxetine Capsule (Prozac; Sarafem®)	
		Paroxetine CR Tablet (Paxil CR®)	Fluoxetine DR Capsule (Generic; Prozac Weekly®)	
		Paroxetine Tablet (Paxil®)	Fluvoxamine CR (Luvox CR®)	
		Paroxetine Tablet (Generic)	Paroxetine Suspension (Generic)	
		Sertraline Tablet (Generic)	Paroxetine CR Tablet (Generic)	
			Paroxetine Mesylate (Pexeva)	
			Sertraline Concentrate (Zoloft; Generic)	
			Sertraline Tablet (Zoloft®)	
7	DERMATOLOGY			
	Antifungals - Topical	Clotrimazole Rx	Benzoic Acid/Salicylic Acid (Bensal HP)	
		Clotrimazole/Betamethasone Cream (Generic)	Butenafine (Mentax®)	
		Clotrimazole/Betamethasone Lotion (Lotrisone®) - Brand	Ciclopirox (CNL8®)	
		Econazole	Ciclopirox (Pedipirox-4)	
		Ketoconazole Cream	Ciclopirox Cream	
		Ketoconazole Shampoo (Rx only)	Ciclopirox Gel	
		Nystatin Cream	Ciclopirox Shampoo	
		Nystatin Ointment	Ciclopirox Solution	
		Nystatin Powder	Ciclopirox Solution (Pedipirox-4)	
		Nystatin/Triamcinolone	Ciclopirox Solution (Penlac)	
		Nystatin/Triamcinolone Cream	Ciclopirox Suspension	
		Nystatin/Triamcinolone Ointment	Clotrimazole/Betamethasone Lotion	
			Clotrimazole / Betamethasone Cream (Lotrisone®) - Brand	
			Ketoconazole (Ketocon Plus®)	
			Ketoconazole Foam	
			Ketoconazole Foam (Extina®)	
			Ketoconazole (Nizoral Shampoo)	
			Ketoconazole (Xolegel®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
			Miconazole (Nuzole®)	
			Miconazole/zinc oxide/white petrolatum (Vusion®)	
			Naftifine (Naftin®)	
			Nystatin (Pediaderm AF®)	
			Oxiconazole (Oxistat®)	
			Sertaconazole (Ertaczo®)	
			Sulconazole (Exelderm®)	
			Terbinafine (Lamisil)	
	Antiparasitic Agents, Topical	Crotamiton Cream (Eurax®)	Benzyl Alcohol (Ulesfia®)	
		Permethrin	Crotamiton Lotion (Eurax®)	
			Lindane	
			Malathion (generic only)	
			Malathion (Ovide® - Brand only)	
			Spinosad (Natroba®)	
	Antiviral Agents, Topical	Acyclovir Ointment (Zovirax®)	Acyclovir Cream (Zovirax®)	
		Penciclovir Cream (Denavir®)	Acyclovir/Hydrocortisone (Xerese®)	
	Atopic Dermatitis	Pimecrolimus (Elidel®)		
	Immunomodulators	Tacrolimus (Protopic®)	NONE	
	Antibiotics, Topical	Gentamicin Sulfate		
		Mupirocin Ointment (Generic)	Mupirocin Cream (Bactroban® Cream)	
			Mupirocin Ointment (Bactroban® Ointment) – Brand Only	
			Mupirocin Ointment (Centany®)	
			Mupirocin Ointment (Centany® Kit)	
			Neomycin/Polymyxin/Pramoxine	
			Retapamulin (Altabax®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
----------	-------------------------------	--------------	------------------------	---------------------------------

STERIODS, TOPICAL	Low Potency	Alclometasone Dipropionate (Aclovate® - Brand Only)	Alclometasone Dipropionate Cream, Ointment (Generic Only)
		Desonide Cream, Ointment (Generic)	Desonate Gel (Generic)
		Hydrocortisone Cream, Lotion, Ointment (Generic)	Desonide/Emollient Combo No. 3 (Desonil Plus®)
			Desonide Lotion (Generic; Desowen; Verdeso®)
			Desonide Cream Kit (Desowen Cream Kit®)
			Desonide Lotion Kit (Desowen Lotion Kit®)
			Desonide Ointment Kit (Desowen Ointment Kit®)
			Fluocinolone Acetonide Shampoo (Capex®)
			Fluocinolone Acetonide (Derma-Smoothie-FS®)
			Hydrocortisone (Texacort®)
Medium Potency			Hydrocortisone Acetate/Urea
			Hydrocortisone/Aloe Gel (Generic; Nuzon®)
			Hydrocortisone/Mineral Oil/Pet Ointment
			Hydrocortisone/Emollient (Pediaderm HC®)
			Triamcinolone (Pediaderm TA®)
		Clocortolone Pivalate (Cloderm®)	
		Fluocinolone Acetonide Cream, Ointment, Solution	Betametasone Valerate (Luxiq®)
		Fluticasone Propionate Cream, Ointment (Generic)	Flurandrenolide Tape (Cordran Tape®)
		Hydrocortisone Butyrate Ointment, Solution	Fluticasone Propionate Cream, Lotion (Cutivate®)
		Hydrocortisone Valerate Cream (Generic)	Hydrocortisone Butyrate Cream (Generic; Locoid Lipocream®)
		Prednicarbate Cream (Dermatop®)	Hydrocortisone Probutate (Pandel®)
			Hydrocortisone Valerate Cream (Westcort®)
			Hydrocortisone Valerate Ointment (Generic)
			Mometasone Furoate Cream, Ointment, Solution (Generic; Elocon®)
			Mometasone Furoate (Mometaxin®)
			Prednicarbate Cream, Ointment (Generic)
			Prednicarbate Ointment (Dermatop®)

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	High Potency	Amcinonide Lotion (Generic)	Amcinonide Cream, Ointment (Generic)	
		Betamethasone Dipropionate Cream, Lotion, Ointment (Generic)	Betamethasone Dipropionate/Prop Glycol Cream, Lotion, Ointment (Generic; Diprolene; Diprolene/AF [®])	
		Betamethasone Valerate Cream, Lotion, Ointment (Generic)	Betamethasone Dipropionate Gel (Generic; Diprolene [®])	
		Betamethasone Valerate Cream, Lotion (Beta Val [®])	Desoximetasone Cream, Gel, Ointment (Generic; Topicort; Topicort LP [®])	
		Fluocinonide Cream; Emollient; Gel; Ointment, Solution (Generic)	Diflorasone Diacetate Cream, Ointment (Generic)	
		Triamcinolone Acetonide Cream, Ointment (Generic)	Fluocinonide Cream (Vanos [®])	
			Halcinonide Cream, Ointment (Halog [®])	
			Triamcinolone Acetonide Aerosol (Kenilag Aerosol [®])	
			Triamcinolone Acetonide Lotion (Generic)	
	Very High Potency			
		Clobetasol Propionate Cream, Gel, Ointment, Solution (Generic)	Clobetasol Propionate Cream (Temovate [®])	
		Clobetasol Propionate Foam (Olux [®])	Clobetasol Propionate Foam (Generic Only)	
		Clobetasol Propionate/Emollient (Generic Only)	Clobetasol Propionate (Clobex Lotion, Shampoo, Spray [®])	
		Halobetasol Propionate Cream, Ointment (Generic)	Clobetasol Propionate - Emollient (Olux-E [®] - Brand Only)	
			Diflorasone Diacetate (Apexicon E [®])	
			Halobetasol Propionate/Ammonium Lactate (Halac, Halonate, Halonate PAC, Ultravate PAC [®])	
8	DIABETES			
	Hypoglycemics, Meglitinides	Repaglinide (Prandin [®])	Nateglinide (Generic)	
			Nateglinide (Starlix [®])	
			Repaglinide/Metformin (Prandimet [®])	
	Hypoglycemics, Thiazolidinediones (TZDs)	Pioglitazone (Actos [®])		
		Pioglitazone/Glimeperide (Duetact [®])	Pioglitazone/Metformin ER (Actoplus Met XR [®])	
		Pioglitazone/Metformin (Actoplus Met [®])	Rosiglitazone/Glimeperide (Avandaryl [®])	
			Rosiglitazone (Avandia [®])	
			Rosiglitazone/Metformin (Avandamet [®])	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Hypoglycemics			
	Insulins & Related Agents	Human Insulin & Pens (Humulin®)	Human Insulin & Pens (Novolin®)	
		Insulin Glargine & Pens (Lantus®)	Insulin Aspart & Pens (Novolog®)	
		Insulin Lispro & Pens (Humalog®)	Insulin Aspart/Insulin Aspart Protamine & Pens (Novolog Mix 70/30®)	
		Insulin Lispro/Protamine Lispro & Pens (Humalog Mix®)	Insulin Detemir & Pens (Levemir®)	
			Insulin Glulisine & Pens (Apidra®)	
	Hypoglycemics			
	Incretin Mimetics/Enhancers	Linagliptin/Metformin (Jentadueto)	Exenatide (Byetta Pens®)	
		Linagliptin (Tradjenta®)	Exenatide Extended-Release (Bydureon®)	
		Liraglutide (Victoza®)	Pramlintide Pens (Symlin Pens®)	
		Pramlintide (Symlin®)	Sitagliptin/Simvastatin (Juvisync)	
		Saxagliptin (Onglyza®)		
		Saxagliptin/Metformin ER (Kombiglyze XR®)		
		Sitagliptin (Januvia®)		
		Sitagliptin/Metformin (Janumet®)		
9	DIGESTIVE DISORDERS			
	Antiemetic/Antivertigo Agents	Aprepitant Oral (Emend®)	Dimenhydrinate Inj	
		Meclizine	Dolasetron IV Inj (Anzemet®)	
		Metoclopramide Inj	Dolasetron Oral (Anzemet®)	
		Metoclopramide Oral (Generics)	Dronabinol Oral (Generic)	
		Ondansetron IV Inj (Generics)	Dronabinol Oral (Marinol®)	
		Ondansetron Oral ODT (Generics)	Fosaprepitant IV Inj (Eliquis®)	
		Ondansetron Oral Tab (Generics)	Granisetron IV Inj	
		Prochlorperazine Inj	Granisetron Oral	
		Prochlorperazine Oral	Granisetron (Granisol Solution)	
		Prochlorperazine Rectal	Granisetron Transdermal (Sancuso®)	
		Promethazine Inj	Metoclopramide (Reglan®) – Brand Only	
		Promethazine Oral	Metoclopramide Ampule	
		Promethazine Rectal	Metoclopramide Oral ODT (Metozolv®)	
		Scopolamine Transdermal (Transderm-Scop®)	Nabilone (Cesamet®)	
		Trimethoprim/zincamide IM Inj	Ondansetron (Zofran®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
		Trimethobenzamide Oral	Ondansetron (Zofran IV*) – Brand Only	
			Ondansetron (Zofran ODT*) – Brand Only	
			Ondansetron Ampule	
			Ondansetron Oral (Zuplenz*)	
			Ondansetron Oral Solution	
			Palonosetron IV Inj (Aloxi*)	
			Prochlorperazine Rectal (Compro*)	
			Promethazine Rectal (50 mg)	
			Trimethobenzamide IM Inj (Tigan*)	
	Bile Acid Salts	Ursodiol Capsule (Generic Only)	Chenodiol (Chenodal*)	
			Ursodiol Tablet	
			Ursodiol USP (Actigall* - Brand Only)	
			Ursodiol (URSO 250*)	
			Ursodiol (URSO Forte*)	
	Pancreatic Enzymes	Creon	Pancreaze	
		Pancrelipase		
		Zenpep		
	Proton Pump Inhibitors	Omeprazole (Generic legend only)	Dexlansoprazole (Dexilant*)	
		Pantoprazole (Generic Only)	Esomeprazole (Nexium*)	
		Pantoprazole Suspension (Protonix*)	Esomeprazole Suspension (Nexium*)	
			Lansoprazole Capsule	
			Lansoprazole Capsule (Prevacid*)	
			Lansoprazole Solutab	
			Lansoprazole Solutab (Prevacid*)	
			Omeprazole (Prilosec*) – Brand Only	
			Omeprazole Suspension (Prilosec*)	
			Omeprazole/Sodium Bicarbonate (Generic legend only)	
			Pantoprazole (Protonix*) – Brand Only	
			Rabeprazole (Aciphex*)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Ulcerative Colitis Agents	Balsalazide	Mesalamine DR (Asacol HD*)	
		Mesalamine ER (Apriso*)	Mesalamine Rectal	
		Mesalamine (Asacol*)	Mesalamine Kit Rectal	
		Mesalamine Suppositories (Canasa*)	Mesalamine Sulfite-free Enema (sRowasa*)	
		Sulfasalazine	Mesalamine MMX (Lialda*)	
		Sulfasalazine DR	Mesalamine Oral (Pentasa*)	
			Olsalazine Oral (Dipentum*)	
10	GROWTH DEFICIENCY			
	Growth Hormones	Somatropin (Norditropin*)	Somatropin (Genotropin*)	
		Somatropin (Nutropin*)	Somatropin (Humatrope*)	
		Somatropin (Nutropin AQ*)	Somatropin (Omnitrope*)	
		Somatropin (Saizen*)	Somatropin (Serostim*)	
			Somatropin (Tev-Tropin*)	
			Somatropin (Zorbtive*)	
11	GOUT AGENTS			
	Antihyperuricemics	Allopurinol	Colchicine (Colcrys*)	
		Probenecid	Febuxostat (Uloric*)	
		Probenecid/Colchicine		
12	HEART DISEASE, HYPERLIPIDEMIA			
	Lipotropics, Other	Cholestyramine	Colesevelam (Welchol*)	
		Cholestyramine/Aspartame	Colestipol Granules	
		Colestipol Tablet - Generic Only	Colestipol Tablet (Colestid*) - Brand Only	
		Fenofibrate (Tricor*)	Colestipol Granule (Colestid*)	
		Fenofibric Acid (Trilipix*)	Ezetimibe (Zetia*)	
		Gemfibrozil	Fenofibrate (Antara*)	
		Niacin ER (Niaspan*)	Fenofibrate (Fenoglide*)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
		Niacin IR (Niacor®)	Fenofibrate (Generic)	
			Fenofibrate (Lipofen®)	
			Fenofibrate (Triglide®)	
			Fenofibric Acid (Generic)	
			Fenofibric Acid (Fibricor®)	
			Omega-3-acid ethyl esters (Lovaza®)	
	Statins & Statin Combination Agents	Atorvastatin (Generic)		
		Fluvastatin (Lescol®)	Amlodipine/Atorvastatin	
		Fluvastatin XL (Lescol XL®)	Amlodipine/Atorvastatin (Caduet®)	
		Lovastatin	Atorvastatin (Lipitor®) – Brand Only	
		Niacin ER/Simvastatin (Simcor®)	Ezetimibe/Simvastatin (Vytorin®)	
		Pravastatin	Lovastatin ER (Altoprev®)	
		Simvastatin (Generic Only)	Niacin ER/Lovastatin (Advicor®)	
			Pitavastatin (Livalo®)	
			Pravastatin (Pravachol®)	
			Rosuvastatin (Crestor®)	
			Simvastatin (Zocor®) – Brand Only	
	HYPERTENSION			
	ACE Inhibitors & Direct Renin Inhibitors	Benazepril (Generic Only)		
		Benazepril/HCTZ	Aliskiren (Tekturna®)	
		Captopril	Aliskiren/HCTZ (Tekturna HCT®)	
		Captopril/HCTZ	Azilsartan Meoxomil (Edarbi®)	
		Enalapril (Generic)	Azilsartan/Chlorthalidone (Edarbyclor®)	
		Enalapril/HCTZ (Generic)	Azilsartan/Chlorthalidone (Prinzide®)	
		Fosinopril	Benazepril (Lotensin®) – Brand Only	
		Lisinopril (Generic Only)	Candesartan (Atacand®)	
		Lisinopril/HCTZ (Generic Only)	Candesartan/HCTZ (Atacand HCT®)	
		Losartan (Generic)	Enalapril (Vasotec) – Brand Only	
		Losartan/HCTZ (Generic)	Enalapril/HCTZ (Vaseretic) – Brand Only	
		Quinapril (Generic)	Eprosartan (Teveten®)	
			Eprosartan/HCTZ (Teveten HCT®)	

[illegible]

Item Nbr	Descriptive Therapeutic Class
-------------	-------------------------------

13	HEMATOLOGIC AGENTS			
	HEMATOPOIETIC AGENTS			
	Erythropoietins	Darbepoetin (Aranesp®)		
		Epoetin alfa (Procrit®)		Epoetin alfa (Epoen®)
	Anticoagulants - refer to			
	HEART DISEASE			
14	HEMODIALYSIS			
	Phosphate Binders	Calcium Acetate (Eliphos®)		
		Sevelamer HCL (RenaGel®)		Calcium Acetate (Generics)
				Calcium Acetate (PhosLo®)
				Calcium Acetate (Phoslyra®)
				Calcium Carbonate/Magnesium Carbonate/FA (Magenebind 400 Rx®)
				Lanthanum (Fosrenol®)
				Sevelamer Carbonate (Renvela®)
15	HORMONE THERAPY			
	Androgenic Agents	Testosterone Transdermal Patch (Androderm®)		Testosterone (Axiron®)
		Testosterone Gel 1% (Androgel®)		Testosterone Gel (Fortesta®)
		Testosterone Gel 1% (Testim®)		
	PITUITARY SUPPRESSIVE AGENTS	Leuprolide Acetate (Lupron Depot®) - Brand Only		
		Leuprolide Acetate (Lupron Depot Kit®)		Goserelin Acetate (Zoladex®)
		Leuprolide Acetate (Lupron Depot-Ped®)		Histrelin (Supprelin LA®)
		Leuprolide Acetate (Lupron Depot-Ped Kit®)		Histrelin (Vantas)
				Leuprolide Acetate (Generic)
				Leuprolide Acetate Kit (Eligard®)
				Nafarelin Acetate Nasal Solution (Synarel®)
				Triptorelin Pamoate (Trelstar®, Trelstar LA®, Trelstar Depot®)

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
			Norfloxacin (Noroxin®)	
			Ofloxacin	
	Antibiotics, Gastrointestinal	Metronidazole Tablet		
		Neomycin	Fidaxomicin (Dificid®)	
		Nitazoxanide (Alinia®)	Metronidazole Capsule	
			Metronidazole Tablet (Flagyl® Tablet) – Brand Only	
			Metronidazole ER (Flagyl ER®)	
			Neomycin (Neo-Fradin®)	
			Rifaximin (Xifaxan®)	
			Tinidazole (Tindamax®)	
			Vancomycin (Vancocin®)	
	Antibiotics, Inhaled	Tobramycin (Tobi®)		
			Azteonam (Cayston®)	
	Macrolides - Ketolides	Azithromycin (Generic Only)		
		Clarithromycin Tablet	Azithromycin (Zithromax®)	
		Erythromycin Tablet (Ery-Tab®)	Azithromycin ER (Zmax®)	
		Erythromycin Base Tablet	Clarithromycin (Biaxin Tablet®)	
		Erythromycin Stearate (Erythrocin®)	Clarithromycin ER	
			Clarithromycin Suspension	
			Erythromycin	
			Erythromycin Base (PCE)	
			Erythromycin Base DR Capsule	
			Erythromycin Ethylsuccinate Tablet (E.E.S. 400)	
			Erythromycin Ethylsuccinate (E.E.S. 200 Suspension)	
			Erythromycin Ethylsuccinate (EryPed 200, 400)	
			Telithromycin (Ketek®)	
	Tetracyclines	Doxycycline Hyclate (generic)		
		Doxycycline Monohydrate 100 mg capsule (Generic Only)	Demeclocycline	
		Minocycline Cap	Doxycycline Calcium Suspension (Vibramycin®)	
		Tetracycline	Doxycycline Hyclate (Doryx®)	
			Doxycycline Hyclate Tablet DR (generic)	
			Doxycycline Hyclate DR (Morgidox)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
			Doxycycline Monohydrate 50 mg capsule	
			Doxycycline Monohydrate 75 mg capsule	
			Doxycycline Monohydrate 100 mg capsule (Monodox®) – Brand Only	
			Doxycycline Monohydrate 150 mg capsule	
			Doxycycline Monohydrate Tablet	
			Doxycycline DR (Oracea®)	
			Minocycline ER - generic	
			Minocycline Tab	
	Vaginal	Clindamycin Vaginal Cream		
		Clindamycin Vaginal Ovules (Cleocin®)	Clindamycin Vaginal Cream (Cleocin®)	
		Metronidazole Vaginal Gel	Clindamycin Vaginal Cream (Clindesse®)	
		Metronidazole Vaginal Gel (Metro-Vaginal®)		
		Metronidazole Vaginal Gel (Vandazole®)		
	OPHTHALMIC ANTIBIOTICS - refer to Ophthalmic Disorders			
	OTIC ANTIBIOTICS - refer to OTIC Agents			
	ANTIFUNGALS			
	Antifungals, Oral			
		Clotrimazole Troches		
		Fluconazole	Fluconazole (Diflucan Tablet®)	
		Griseofulvin Suspension	Flucytosine (Ancobon®)	
		Griseofulvin (Gris-Peg®)	Griseofulvin Tablets (Grifulvin V®)	
		Ketoconazole	Itraconazole	
		Nystatin	Itraconazole Solution (Sporanox®)	
		Terbinafine (no granules)	Nystatin Powder (Oral)	
			Posaconazole (Noxafil®)	
			Terbinafine (Terbinafin®)	
			Terbinafine Granules (Lamisil Granules®)	
			Voriconazole (Generic)	
			Voriconazole (VFEND®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	HEPATITIS AGENTS			
	Hepatitis C Agents			
		Boceprevir (Victrelis®)		
		Ribavirin Tablet	Consensus Interferon (Infergen®)	
		Peginterferon alfa 2A (Pegasys®)	Peginterferon alfa 2B (Peg-Intron®)	
		Telaprevir (Incivek®)	Peginterferon alfa 2B (Peg-Intron Redipen®)	
			Ribavirin Capsule	
			Ribavirin (Ribasphere, Ribasphere Ribapak)	
			Ribavirin (Rebetol)	
17	MULTIPLE SCLEROSIS			
	Multiple Sclerosis Agents	Glatiramer (Copaxone®)		
	(Immunomodulatory Agents)	Interferon beta - 1a (Avonex®)	Dalfampridine (Ampyra®)	
		Interferon beta - 1a (Rebif®)	Fingolimod (Gilenya®)	
		Interferon beta - 1b (Betaseron®)	Interferon beta-1b (Extavia®)	
18	OPHTHALMIC DISORDERS			
	Allergic Conjunctivitis			
		Cromolyn Sodium		
		Loteprednol (Alrex®)	Alcaftadine (Lastacaft®)	
		Olopatadine HCl (Pataday®)	Azelastine HC (Generic; Optivar®)	
			Bepotastine (Bepreve®)	
			Emedastine Difumarate (Emadine®)	
			Epinastine (Generic; Elestat®)	
			Lodoxamide Tromethamine (Alomide®)	
			Nedocromil Sodium (Alocril®)	
			Olopatadine HCl (Patanol®)	
			Pemirolast Potassium (Alamast®)	
	Glaucoma Agents			
	Intraocular Pressure (IOP)	Betaxolol		
			Apraclonidine (Generic; Iopidine®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Reducers	Betaxolol (Betoptic S*)	Bimatoprost (Lumigan 2.5ml; 5ml; 7.5ml*)	
		Brimonidine 0.15% (Alphagan P 0.15% - Brand Only)	Brimonidine 0.1% (Alphagan P 0.1%*)	
		Brimonidine 0.2% (Generic)	Brimonidine 0.15% (Generic only)	
		Brimonidine/Timolol (Combigan*)	Dorzolamide (Trusopt* - Brand Only)	
		Brinzolamide (Azopt*)	Dorzolamide/Timolol (Cosopt* - Brand Only)	
		Carteolol	Latanoprost (Xalatan* - Brand Only)	
		Dorzolamide (Generic only)	Levobunolol (Betagan* - Brand Only)	
		Dorzolamide/Timolol (Generic only)	Timolol (Timoptic*)	
		Latanoprost (Generic only)		
		Levobunolol (Generic only)		
		Metipranolol (Generic; Optipranolol*)		
		Pilocarpine		
		Timolol (Generic; Betimol*)		
		Timolol LA (Istalol*)		
		Travoprost (Travatan Z*)		
	Ophthalmics, Antibiotic	Besifloxacin (Besivance*)	Azithromycin (AzaSite*)	
		Ciprofloxacin Ointment (Ciloxan*)	Bacitracin	
		Ciprofloxacin Solution (Generic)	Bacitracin/Polymyxin B Ointment	
		Erythromycin	Gatifloxacin 0.5% (Zymaxid*)	
		Garamycin Drops	Levofloxacin (Generic; Iquix; Quixin*)	
		Garamycin Ointment	Natamycin (Natacyn*)	
		Gatifloxacin 0.3% (Zymar*)	Neomycin-Polymyxin-Gramacidin	
		Gentamicin Drops	Ofloxacin Solution (Ocuflox* - Brand Only)	
		Gentamicin Ointment		
		Moxifloxacin (Moxeza; Vigamox*)		
		Neomycin-Polymyxin-Bacitracin Ointment		
		Ofloxacin Solution (Generic Only)		
		Polymyxin B/Trimethoprim (Generic; Polyttrim*)		
		Sulfacetamide (Generic; Bleph-10*)		
		Tobramycin (Generic; Tobrex*)		
	Ophthalmics, Antibiotic- Steroid Combos	Gentamicin/Prednisolone (Pred-G; Pred-G S.O.P. *)	Neomycin/Polymyxin B/Hydrocortisone	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
		Acetic Acid/Aluminum	Antipyrine/Benzocaine/Policosanol (Otic Care®)	
		Antipyrine/Benzocaine	Antipyrine/Benzocaine/Zinc (Neotic; Otozin®)	
		Benzocaine (Pinnacaine®)	Chloroxylenol/Benzocaine/Hydrocortisone (Myoxin; Trioxin®)	
		Chloroxylenol/Pramoxine	Chloroxylenol/Pramoxine/Zinc/Glycerine (Zinotic; Zinotic ES®)	
		Chloroxylenol/Pramoxine (Pramotic®)		
		Pramoxine HC		
21	OSTEOPOROSIS			
	Bone Resorption Suppression Agents	Alendronate Tablets (Generic)	Alendronate (Fosamax®) – Brand Only	
		Calcitonin-Salmon Nasal (Miacalcin®) – Brand Only	Alendronate Solution (Fosamax Solution®)	
			Alendronate/Vit D (Fosamax Plus D®)	
			Calcitonin-Salmon Nasal (Fortical®)	
			Calcitonin - Salmon Nasal (Generics)	
			Denosumab (Prolia®)	
			Etidronate Disodium (Generics)	
			Etidronate (Didronel®)	
			Ibandronate Sodium (Boniva®)	
			Raloxifene (Evista®)	
			Risedronate (Actonel®)	
			Risedronate DR (Atelvia®)	
			Teriparatide Subcutaneous (Forteo®)	
22	PAIN MANAGEMENT			
	Analgesics/Anesthetic, Topical	Diclofenac Sodium Gel (Voltaren®)	Diclofenac Epilamine Patch (Flector®)	
		Lidocaine Patch (Lidoderm®)	Diclofenac Sodium (Pennsaid®)	
	Analgesics, Narcotics Short Acting	Acetaminophen w/Codeine (Generic)	Carisoprodol Compound-Codeine	
		Butalbital Compound with Codeine	Capital w/Codeine	
		Butorphanol Tartrate	Codeine/Acetaminophen (Cocet®, Cocet Plus®)	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Codeine	Codeine	Codeine/Acetaminophen (Tylenol #4)	
	Dihydrocodeine Bitartrate/Acetaminophen/Caffeine (Generics)	Dihydrocodeine Bitartrate/Acetaminophen/Caffeine (Generics)	Dihydrocodeine Bitartrate/Aspirin/Caffeine (Synalgos DC*)	
	Hydrocodone/Acetaminophen (Generic)	Hydrocodone/Acetaminophen (Generic)	Dihydrocodeine Bitartrate/Acetaminophen/Caffeine (Trexix*)	
	Hydrocodone/Ibuprofen (Generic)	Hydrocodone/Ibuprofen (Generic)	Fentanyl Buccal (Generics)	
	Hydromorphone Tablet	Hydromorphone Tablet	Fentanyl Buccal (Actiq*)	
	Morphine Solution, IR Tablet	Morphine Solution, IR Tablet	Fentanyl Buccal (Fentora*)	
	Oxycodone	Oxycodone	Fentanyl Buccal (Onsolis*)	
	Oxycodone (Roxicodone*)	Oxycodone (Roxicodone*)	Fentanyl Sublingual (Abstral*)	
	Oxycodone/Acetaminophen	Oxycodone/Acetaminophen	Hydrocodone/Acetaminophen (Hycet*)	
	Oxycodone/Acetaminophen (Roxicet*)	Oxycodone/Acetaminophen (Roxicet*)	Hydrocodone/Acetaminophen (Xodol*)	
	Oxycodone w/Aspirin	Oxycodone w/Aspirin	Hydrocodone/Acetaminophen (Lorcet*)	
	Oxycodone/Ibuprofen	Oxycodone/Ibuprofen	Hydrocodone/Acetaminophen (Lortab*)	
	Pentazocine/Acetaminophen	Pentazocine/Acetaminophen	Hydrocodone/Acetaminophen (Norco*)	
	Pentazocine/Naloxone	Pentazocine/Naloxone	Hydrocodone/Acetaminophen (Vicodin*)	
	Tramadol (Generic)	Tramadol (Generic)	Hydrocodone/Acetaminophen (Zamcet*)	
	Tramadol/Acetaminophen (Generic)	Tramadol/Acetaminophen (Generic)	Hydrocodone/Acetaminophen (Zolvit*)	
			Hydrocodone/Acetaminophen (Zydol*)	
			Hydrocodone/Ibuprofen (Ibudone*)	
			Hydrocodone/Ibuprofen (Repexain*)	
			Hydrocodone/Ibuprofen (Vicoprofen*)	
			Hydromorphone (Dilaudid*)	
			Hydromorphone Suppositories	
			Levorphanol	
			Meperidine	
			Meperidine (Demerol*)	
			Morphine Concentrate Solution	
			Morphine Suppositories	
			Opium Tincture	
			Oxycodone/Acetaminophen (Magnacet*)	
			Oxycodone/Acetaminophen (Percocet*)	
			Oxycodone/Acetaminophen (Primalen*)	
			Oxycodone/Acetaminophen (Xolox*)	
			Oxycodone/Aspirin (Percodan*)	
			Oxycodone (Oxecta*)	

[illegible]

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
	Skeletal Muscle Relaxants	Baclofen	Carisoprodol	
		Chlorzoxazone	Carisoprodol Compound	
		Cyclobenzaprine	Carisoprodol (Soma 250 mg*)	
		Methocarbamol	Chlorzoxazone (Lorzone)	
		Tizanidine (Generics)	Chlorzoxazone (Parafon Forte DSC)	
			Cyclobenzaprine (Fexmid*)	
			Cyclobenzaprine ER (Generic)	
			Cyclobenzaprine ER (Amrix*)	
			Dantrolene Sodium	
			Metaxalone	
			Methocarbamol (Robaxin)	
			Orphenadrine	
			Orphenadrine Compound	
			Tizanidine (Zanaflex*)	
	Cytokine and CAM Antagonists	Adalimumab Injection (Humira IJ Kit; Humira Kit*)	Abatacept (Orencia Injection; Orencia Sub-Q*)	
		Certolizumab Pegol (Cimzia Kit; Syringe Kit*)	Alefacept Injection (Amevive*)	
		Etanercept Injection (Enbrel Kit; Pen; Disp Syringe*)	Anakinra Injection (Kineret*)	
			Golimimumab (Simponi Pen; Disp Syringe*)	
			Infliximab Injection (Remicade*)	
			Tocilizumab (Actemra*)	
23	PARKINSON'S			
	Antiparkinson Agents -	Benzotropine		
	Anticholinergic and Other	Carbidopa/ Levodopa	Bromocriptine	
		Carbidopa/ Levodopa ER (Generic Only)	Carbidopa/ Levodopa ER (Sinemet CR* - Brand Only)	
			Carbidopa/ Levodopa ODT	

Item Nbr	Descriptive Therapeutic Class	Drugs on PDL	Drugs which Require PA	Effective Date: July 1, 2012
24	SEDATIVE/HYPNOTICS	Levodopa/Carbidopa/Entacapone (Stalevo®)	Entacapone (Comtan®)	
		Pramipexole (Generic)	Pramipexole (Mirapex®)	
		Ropinirole (Generic Only)	Pramipexole ER (Mirapex ER®)	
		Selegiline Tablet (Generic)	Rasagiline (Azilect®)	
		Trihexyphenidyl Elixir	Ropinirole (Requip® - Brand Only)	
		Trihexyphenidyl Tablet	Ropinirole ER (Requip XL®)	
			Selegiline Capsule	
			Selegiline (Zelapar®)	
			Tolcapone (Tasmar®)	
		Chloral Hydrate Syrup	Chloral Hydrate (Somnote®)	
		Temazepam (Generic)	Doxepin (Silenor®)	
		Triazolam (Generic Only)	Estazolam	
		Zaleplon (Generic Only)	Eszopiclone (Lunesta®)	
		Zolpidem (Generic Only)	Flurazepam	
			Quazepam (Doral®)	
			Ramelteon (Rozerem®)	
			Temazepam (Restoril®)	
			Temazepam 7.5mg (Generic; Restoril®)	
			Temazepam 22.5mg (Generic; Restoril®)	
			Triazolam (Halcion® - Brand Only)	
			Zaleplon (Sonata - Brand Only)	
			Zolpidem (Ambien® - Brand Only)	
			Zolpidem Sublingual (Eduar; Zolpimist®)	
			Zolpidem ER (Generic; Ambien CR®)	
25	UROLOGY INCONTINENCE Bladder Relaxant Preparations			
		Fesoterodine Fumarate (Toviaz®)	Darifenacin (Enablex®)	
		Oxybutynin	Flavoxate	
		Solifenacin (VESicare®)	Oxybutynin ER	

[illegible]